Cialis: first PDE5 inhibitor licensed for benign prostatic hyperplasia

2 January 2013

Tadalafil (Cialis) has been approved for the treatment of benign prostatic hyperplasia (BPH).

Tadalafil (Cialis) provides a new treatment option for the management of benign prostatic hyperplasia | SCIENCE PHOTO LIBRARY

The phosphodiesterase 5 inhibitor is thought to relieve BPH symptoms by relaxing smooth muscle and increasing blood flow to the bladder, prostate and urethra.

Efficacious from as early as week one

The efficacy and safety of tadalafil in BPH was displayed in four 12-week clinical studies that enrolled over 1,500 men. In each study, treatment with tadalafil 5mg daily improved total International Prostate Symptom score by around two points more than placebo, with improvements being observed as early as week one.

Suitable for BPH with erectile dysfunction

Cialis can be used in patients with BPH who require treatment for erectile dysfunction (ED) as the 5mg once-daily dose is licensed for both indications, provided the patient requires frequent use in ED (at least twice weekly).

View Cialis drug record

Further information: Lilly Eli & Co Ltd

Follow MIMS on Twitter